quantisnow
FeedTopReportsPricing
⌘K
Live feed
06:00:00·121d
PRRelease
Caribou Biosciences Inc. logo
GT Biopharma Inc. logo
Lyell Immunopharma Inc. logo
+2

Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge

CRBU· Caribou Biosciences Inc.GTBP· GT Biopharma Inc.LYEL· Lyell Immunopharma Inc.NRIX· Nurix Therapeutics Inc.SLS· SELLAS Life Sciences Group Inc.
Health Care
Original source

Companies

  • CRBU
    Caribou Biosciences Inc.
    Health Care
  • GTBP
    GT Biopharma Inc.
    Health Care
  • LYEL
    Lyell Immunopharma Inc.
    Health Care
  • NRIX
    Nurix Therapeutics Inc.
    Health Care
  • SLS
    SELLAS Life Sciences Group Inc.
    Health Care

Recent analyst ratings

  • Apr 10LYELUpdateNeedham$44.00
  • Mar 9LYELUpdateCitizens$34.00
  • Jan 8NRIXUpdateMorgan Stanley$36.00
  • Dec 9LYELUpdateH.C. Wainwright$45.00
  • Nov 24NRIXUpdateTruist$30.00
  • Oct 21NRIXUpdateMizuho$24.00

Related

  • SEC20h
    SEC Form DEFA14A filed by SELLAS Life Sciences Group Inc.
  • SEC20h
    SEC Form DEF 14A filed by SELLAS Life Sciences Group Inc.
  • PR2d
    Nurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026
  • SEC9d
    SEC Form EFFECT filed by Lyell Immunopharma Inc.
  • SEC13d
    SEC Form PRE 14A filed by Caribou Biosciences Inc.
  • ANALYST14d
    Needham initiated coverage on Lyell Immunopharma with a new price target
  • SEC16d
    SEC Form 10-Q filed by Nurix Therapeutics Inc.
  • SEC16d
    Nurix Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022